---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-068659"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2025-07-17T23:59:59+00:00"
generated_at: "2026-05-18T05:59:11.127529+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acurx shareholders approve reverse split, equity plan increase, and director elections at annual meeting

## Summary
- All six proposals passed at July 17 meeting; 74.38% of shares represented.
- Reverse stock split authorized at ratio 1:10 to 1:30; board to set timing and exact ratio.
- 2021 Equity Plan share reserve increased from 177,448 to 2,677,448 shares.
- Directors Sailer and Harrison re-elected; auditor CohnReznick ratified; warrant exercise and ELOC approved for Nasdaq compliance.

## SEC filing metadata
- accession: 0001104659-25-068659
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2025-07-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465925068659/0001104659-25-068659-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465925068659/tm2521097d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-068659
- JSON: https://secwatch.observer/filing/0001104659-25-068659.json
- Plain text: https://secwatch.observer/filing/0001104659-25-068659.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.